Hida S, Kawakita M, Takenawa J, Fukuzawa S, Okuno H, Yamauchi T, Oishi K, Nishio Y, Takeuchi H, Okada K
Hinyokika Kiyo. 1986 Dec;32(12):1849-58.
Between 1983 and 1985, six patients with advanced testicular cancer were treated with 3 cycles of vinblastine, actinomycin D, bleomycin, cyclophosphamide and cisplatinum (VAB-6 combination chemotherapy without maintenance). The histology of the primary tumor was seminoma in one patient and nonseminomatous germ cell testicular tumor (NSGCTT) in 5. Five men with stage III or bulky stage II diseases received no prior chemotherapy but one had received another chemotherapy without cisplatinum. Two patients showed a complete response to chemotherapy. Three were partial responders free of disease after a debulking operation and additional chemotherapy. The other patient who had NSGCTT had recurrence 5 months after the last induction chemotherapy and received additional chemotherapy (PVeBV regimen). Median follow-up was 16 months (range 2 to 28 months) and all patients are alive with no evidence of disease. Severe myelosuppression and serious renal toxicity were not experienced. Marked, but transient elevation of serum transaminase were observed in all patients. These data suggest that this protocol is highly effective and minimally toxic in the treatment of disseminated testicular tumor.
1983年至1985年间,6例晚期睾丸癌患者接受了3个周期的长春碱、放线菌素D、博来霉素、环磷酰胺和顺铂治疗(VAB - 6联合化疗,无维持治疗)。原发肿瘤的组织学类型为1例精原细胞瘤,5例非精原细胞性生殖细胞睾丸肿瘤(NSGCTT)。5例III期或大块II期疾病的男性患者未接受过先前的化疗,但1例曾接受过不含顺铂的其他化疗。2例患者对化疗表现出完全缓解。3例患者在减瘤手术和额外化疗后部分缓解且无疾病。另1例患有NSGCTT的患者在最后一次诱导化疗后5个月复发并接受了额外化疗(PVeBV方案)。中位随访时间为16个月(范围2至28个月),所有患者均存活且无疾病证据。未出现严重骨髓抑制和严重肾毒性。所有患者均观察到血清转氨酶显著但短暂升高。这些数据表明该方案在治疗播散性睾丸肿瘤方面高效且毒性极小。